Semaglutide News and Research

Latest Semaglutide News and Research

Tirzepatide reveals a brain signal that predicts returning food preoccupation

Researchers implanted electrodes in the human nucleus accumbens to track brain activity during severe food preoccupation in an individual taking tirzepatide. They found that a delta–theta biomarker disappeared during symptom-free periods and re-emerged weeks before relapse, suggesting a possible neural marker of vulnerability to dysregulated eating.

18 Nov 2025

Brain recordings reveal short-lived effects of tirzepatide on food cravings

A rare glimpse into the brain activity of a patient with obesity and loss of control eating on tirzepatide, marketed as Mounjaro and Zepbound, revealed that the medication suppresses signaling in the brain's "reward center" thought to be involved in food noise – but only temporarily.

17 Nov 2025

High protein breakfasts help you feel fuller but do not change how much you eat later

High protein breakfasts, whether plant or animal-based, boosted GLP-1 and PYY and modestly reduced appetite compared with a low protein, high carbohydrate meal. Despite these hormonal and appetite changes, lunchtime energy intake remained unchanged in both younger and older adults.

13 Nov 2025

Off-label GLP-1 use highlights the cultural pressures driving body anxieties

New obesity drugs that were designed to treat diabetes and obesity are increasingly being used off-label by people without these conditions to achieve slimness and social approval rather than health gains. This perspective maps how such pharmacological thinness interacts with stigma, beauty ideals, digital culture, and inequality, and calls for multinational, intersectional research to understand its full impact.

13 Nov 2025

What The Health? From KFF Health News: The government is open

The longest federal government shutdown in history is over, after a handful of House and Senate Democrats joined most Republicans in approving legislation that funds the government through January. Despite Democrats' demands, the package did not include an extension of the expanded tax credits that help most Affordable Care Act enrollees afford their plans — meaning most people with ACA plans are slated to pay much more toward their premiums next year.

13 Nov 2025

Mursla Bio collaborates with a leading global pharma company to advance biomarker-guided precision medicine in MASH

Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to advance precision diagnostics and significantly improve chronic disease outcomes for at-risk patients, today announced a collaboration with a leading global pharmaceutical company recognized for its expertise in precision medicine and biomarker-guided drug development.

From Mursla Bio 13 Nov 2025

GLP-1 drugs linked to improved survival in colon cancer patients

A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor agonists - the class of drugs behind Ozempic, Wegovy and Mounjaro, for example - may do more than regulate blood sugar and weight.

11 Nov 2025

Metformin shows promise in treating AFib recurrence after ablation

People with atrial fibrillation (AFib) and obesity may have fewer episodes of AFib after ablation if they take the diabetes medication metformin in addition to standard care, according to a preliminary, late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.

11 Nov 2025

Novel triple receptor agonist shows potent efficacy in lowering high triglycerides

In a small, short duration trial (12 weeks), a new medication called DR10624 reduced triglyceride levels in most patients with severe hypertriglyceridemia by more than 60%, according to a preliminary late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.

11 Nov 2025

GLP-1 drugs beat metformin for weight control in teens with type 2 diabetes

In youth newly diagnosed with type 2 diabetes, GLP-1–based therapies, including semaglutide and tirzepatide, achieved similar blood sugar control but significantly greater reductions in body mass index than metformin. These findings highlight the potential of high-potency GLP-1 agents as effective monotherapy options in managing obesity and glycemic control in adolescents.

10 Nov 2025

Diabetes drugs semaglutide and tirzepatide show real-world heart benefits

In a large real-world analysis across three U.S. healthcare databases, semaglutide and tirzepatide showed cardiovascular benefits consistent with randomized trials. Semaglutide lowered heart attack and stroke risk versus sitagliptin, while tirzepatide performed comparably to dulaglutide and semaglutide over one year.

10 Nov 2025

Weight loss drugs used by patients with high triglycerides do not increase pancreatitis risk

In a major new study, researchers from Intermountain Health in Salt Lake City have found that weight loss drugs used by patients who have high triglycerides do not increase their risk of pancreatitis or adverse cardiac events.

10 Nov 2025

Genetic and cellular mechanisms underlying steatotic liver disease

Steatotic liver disease (SLD), mainly encompassing metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-related liver disease (ALD), and metabolic dysfunction and ALD (MetALD), has emerged as the dominant cause of chronic liver disease worldwide, displacing viral hepatitis as the primary aetiology.

10 Nov 2025

Do GLP-1 drugs cause cancer? New review says no, may even protect

A comprehensive review in The Journal of Clinical Investigation finds no overall link between GLP-1 receptor agonists and increased cancer risk, countering early safety concerns. Instead, evidence suggests possible protective effects for certain cancers, supported by metabolic and immune-modulating mechanisms.

4 Nov 2025

GLP-1 drugs calm inflammation beyond diabetes and weight loss

This Journal of Clinical Investigation review describes how glucagon-like peptide-1 (GLP-1)–based medicines reduce systemic and tissue inflammation through both weight-dependent and weight-independent mechanisms. It details preclinical and clinical evidence linking GLP-1 receptor activation to cardiovascular, renal, hepatic, neural, and joint anti-inflammatory effects while outlining uncertainties and future research needs.

4 Nov 2025

Resistance exercise may offer greater benefits for preventing diabetes and obesity

Running may help burn calories, but when it comes to preventing diabetes and obesity, pumping iron might have the edge, according to preclinical findings from the Fralin Biomedical Research Institute at VTC.

4 Nov 2025

Low-dose aspirin helps reduce the incidence of major cardiovascular event among diabetic individuals

People with Type 2 diabetes (T2D) and an elevated risk for cardiovascular disease (CVD) who took low-dose aspirin were less likely to experience a major cardiovascular event, including heart attack, stroke or death, than people with T2D at similar CVD risk who did not take low-dose aspirin, according to a preliminary study to be presented at the American Heart Association's Scientific Sessions 2025.

3 Nov 2025

Healthy lifestyle habits plus GLP-1 RA drugs can improve heart health of people with Type 2 diabetes

People with Type 2 diabetes who combined healthy lifestyle habits with GLP-1 receptor agonist (GLP-1 RA) medications had a greater reduction in risk of major adverse cardiovascular events, including heart attack, stroke or cardiovascular disease death, compared to people only taking the medication, according to a preliminary study to be presented at the American Heart Association's Scientific Sessions 2025.

3 Nov 2025

WHO reviews highlight limited long-term data on GLP-1 drug safety

Three new Cochrane reviews find evidence that GLP-1 drugs result in clinically meaningful weight loss, but industry-funded studies raise questions. The reviews were commissioned by the World Health Organization (WHO) to inform upcoming guidelines on the use of these drugs to treat obesity.

30 Oct 2025

Diabetes remission possible with GLP-1 drugs, Italian study confirms

In a large real-world Italian cohort, GLP-1 receptor agonist therapy led to measurable rates of type 2 diabetes remission, depending on how remission was defined. The most pragmatic definition (Remission 3) was linked to improved glycemia, weight, and a lower risk of microvascular and cardiovascular events.

29 Oct 2025

Semaglutide News and Research

Latest Semaglutide News and Research

Tirzepatide reveals a brain signal that predicts returning food preoccupation

Brain recordings reveal short-lived effects of tirzepatide on food cravings

High protein breakfasts help you feel fuller but do not change how much you eat later

Off-label GLP-1 use highlights the cultural pressures driving body anxieties

What The Health? From KFF Health News: The government is open

Mursla Bio collaborates with a leading global pharma company to advance biomarker-guided precision medicine in MASH

GLP-1 drugs linked to improved survival in colon cancer patients

Metformin shows promise in treating AFib recurrence after ablation

Novel triple receptor agonist shows potent efficacy in lowering high triglycerides

GLP-1 drugs beat metformin for weight control in teens with type 2 diabetes

Diabetes drugs semaglutide and tirzepatide show real-world heart benefits

Weight loss drugs used by patients with high triglycerides do not increase pancreatitis risk

Genetic and cellular mechanisms underlying steatotic liver disease

Do GLP-1 drugs cause cancer? New review says no, may even protect

GLP-1 drugs calm inflammation beyond diabetes and weight loss

Resistance exercise may offer greater benefits for preventing diabetes and obesity

Low-dose aspirin helps reduce the incidence of major cardiovascular event among diabetic individuals

Healthy lifestyle habits plus GLP-1 RA drugs can improve heart health of people with Type 2 diabetes

WHO reviews highlight limited long-term data on GLP-1 drug safety

Diabetes remission possible with GLP-1 drugs, Italian study confirms

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Semaglutide News and Research

Latest Semaglutide News and Research

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Newsletters you may be interested in